Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Research & Development: 2020-2024

Historic Research & Development for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $25.6 million.

  • Xeris Biopharma Holdings' Research & Development rose 27.09% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 13.67%. This contributed to the annual value of $25.6 million for FY2024, which is 14.41% up from last year.
  • Xeris Biopharma Holdings' Research & Development amounted to $25.6 million in FY2024, which was up 14.41% from $22.3 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Research & Development peaked at $25.6 million during FY2024, and registered a low of $20.9 million during FY2020.
  • In the last 3 years, Xeris Biopharma Holdings' Research & Development had a median value of $22.3 million in 2023 and averaged $23.0 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Research & Development rose by 20.26% in 2021 and then dropped by 16.67% in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Research & Development (Yearly) stood at $20.9 million in 2020, then increased by 20.26% to $25.2 million in 2021, then fell by 16.67% to $21.0 million in 2022, then climbed by 6.56% to $22.3 million in 2023, then rose by 14.41% to $25.6 million in 2024.